The purpose of this study is to assess the safety and pharmacokinetics of MK-5890 when
administered alone and in combination with pembrolizumab (MK-3475) in adults with advanced
solid tumors. The initial course of MK-5890 monotherapy or MK-5890 plus pembrolizumab
combination therapy will be for up to 35 administrations (approximately 2 years). The safety
and pharmacokinetics of MK-5890 when administered with pembrolizumab, pemetrexed and
carboplatin in adults with nonsquamous non-small cell lung cancer (NSCLC) and MK-5890 when
administered with pembrolizumab and nab-paclitaxel in adults with triple-negative breast
cancer (TNBC) will also be assessed.
Participants receiving MK-5890 monotherapy who experience disease progression may be eligible
to switch to receiving MK-5890 plus pembrolizumab combination therapy for up to 35 cycles
(approximately 2 years) at the discretion of the Investigator and approval of the Sponsor.
Non-Small Cell Lung Cancer,
Triple Negative Breast Cancer,
Triple Negative Breast Neoplasms,
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.